PerCP/Cyanine5.5 anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Raised against granulocytes of mouse origin

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 10⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser

Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C¹⁹. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A8¹⁹. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.4²⁰.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity², in vivo depletion^3-5,9, immunoprecipitation¹, immunohistochemical staining⁶ (including paraffin-embedded sections^9,16,33-35, acetone-fixed frozen sections¹¹ and zinc-fixed sections¹⁵), and Western blotting⁷. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)²⁰.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Application References

(PubMed link indicates BioLegend citation)

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)

Product Citations

1. Meyers AK, et al. 2023. Cell Rep. 42:111941. PubMed
2. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
3. Däbritz J, et al. 2016. Sci Rep. 6:20584. PubMed
4. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
5. Wang X, et al. 2019. Cell Res. 29:787. PubMed
6. Lang J, et al. 2020. Nat Commun. 11:1338. PubMed
7. Shiroshita K, et al. 2022. Cell Rep Methods. 2:100354. PubMed
8. Sheng Y, et al. 2023. Cancers (Basel). 15:. PubMed
9. Tripathi H, et al. 2020. J Mol Cell Cardiol. 149:95. PubMed
10. McNamara HA, et al. 2020. Cell Host Microbe. 572:28. PubMed
11. Kim JS, et al. 2020. Immunity. 54(1):176-190.e7. PubMed
12. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
13. Giambra V et al. 2018. Cell stem cell. 23(5):714-726 . PubMed
14. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
15. Liang Q, et al. 2022. iScience. 25:104043. PubMed
16. Lutzmann M, et al. 2019. Cell Rep. 28:2851. PubMed
17. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
18. Wang H, et al. 2019. Immunotherapy. 11:101. PubMed
19. Wang X, et al. 2020. Signal Transduct Target Ther. 5:35. PubMed
20. Kobayashi H, et al. 2020. STAR Protoc. 1:100078. PubMed
21. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
22. Lebratti T, et al. 2021. eLife. 10:00. PubMed
23. Nakamura‐Ishizu A et al. 2018. Cell reports. 25(7):1772-1785 . PubMed
24. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
25. Stivala S, et al. 2019. J Clin Invest. 130:1596. PubMed
26. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
27. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
28. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
29. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
30. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
31. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
32. Li L, et al. 2015. J Am Soc Nephrol. 26: 2183-2197. PubMed
33. Hönes J, et al. 2017. Sci Rep. . 10.1038/s41598-017-15866-9. PubMed
34. Vogel AB, et al. 2021. Nature. 592:283. PubMed
35. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
36. Bugler-Lamb AR, et al. 2021. Mol Metab. 49:101197. PubMed
37. Mishra A, et al. 2012. J Biol Chem. 287:44173. PubMed
38. Tripathi H, et al. 2020. Stem Cell Rev Rep. 0.953472222. PubMed
39. Chatterjee D, et al. 2021. Cell Reports. 35(2):108996. PubMed
40. Haka A, et al. 2012. PLoS One. 7:e44823. PubMed
41. Jamali A, et al. 2020. Cell Reports. 32(9):108099. PubMed
42. Zhang P, et al. 2022. Nat Commun. 13:1588. PubMed
43. Garcia-Bonilla L, et al. 2014. J Immunol. 193:2531. PubMed
44. Arcipowski K, et al. 2016. PLoS One. 11: 0162515. PubMed
45. Giampazolias E, et al. 2021. Cell. . PubMed
46. Kobayashi H, et al. 2020. Cell Reports. 28(1):145-158.e9.. PubMed
47. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
48. Li L, et al. 2014. J Immunol. 192:1034. PubMed
49. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
50. Wang Z, et al. 2020. J Cell Mol Med. . PubMed
51. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
52. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
53. Deliyannis G, et al. 2021. JCI Insight. 6:. PubMed
54. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
55. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
56. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
57. Zhang X, et al. 2022. J Exp Clin Cancer Res. 41:246. PubMed
58. Matsushita N, et al. 2016. Sci Rep. 6:31266. PubMed
59. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
60. Winter C, et al. 2018. Cell Metab. 28:175. PubMed
61. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
62. Petriello MC, et al. 2018. Toxicol Sci. 162:548. PubMed
63. Man N, et al. 2021. JCI Insight. 6:. PubMed
64. Zheng QY, et al. 2020. FASEB J. 34:10590. PubMed
65. Zheng QY, et al. 2019. Front Immunol. 10:1866. PubMed
66. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed

RRID

AB_893558 (BioLegend Cat. No. 108427)
AB_893558 (BioLegend Cat. No. 108428)

Antigen Details

Structure

21-25 kD

Distribution

Granulocytes, monocytes

Cell Type

Granulocytes, Monocytes, Neutrophils

Biology Area

Immunology, Innate Immunity

Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID

17067 View all products for this Gene ID 546644 View all products for this Gene ID

UniProt

View information about Ly-6G Ly-6C on UniProt.org

Documentation

• Technical data sheet
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

Certificate of Analysis